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Abstract 
Celiac disease is an autoimmune disease driven by an immune response to gluten 
peptides. The disease is strongly associated with the MHC class II molecule HLA-
DQ2.5. The similar molecule HLA-DQ2.2 is not associated with celiac disease. The 
two molecules have very similar peptide binding domains and are both able to bind 
gluten T-cell epitopes. A marked difference in CLIP presentation at the peptide 
binding groove has been observed between the two HLA molecules. HLA-DQ2.5 
presents large amounts of CLIP peptides in the binding groove, while HLA-DQ2.2 
does not. There are only 10 polymorphic residues in the membrane distal domains of 
these HLA- molecules. This thesis is part of a large study using site-directed 
mutagenesis, flow cytometry and mass spectrometry to clarify which, if any, of these 
polymorphic residues are responsible for the difference seen in CLIP presentation and 
stability. This investigation may also elucidate part of the differences seen in celiac 
disease association. Results from parts of the study have been published by 
Fallang.et.al.1 showing that the polymorphism in position α22 is of great importance 
for the presentation and stability of CLIP and other peptides bound to HLA-DQ2.2 
and HLA-DQ2.5.  
Findings presented in this thesis show that the polymorphisms in positions α31, α37 
and α72 also have an effect on CLIP presentation and stability in HLA-DQ2.5 and 
HLA-DQ2.2. Their effect appears to be the opposite of the one described in the 
previous study, and may help explain some of the results presented there. 
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HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid   
HF High fidelity   
HLA Human Leukocyte Antigen   
Ii Invariant Chain   
LB Luria-Bertani medium   
MALDI Matrix-assisted laser desorption   
MHC Major Histocompatibility Complex   
MQ Milli-Q   
min. Minute   
NEB New England Biolabs   
NP-40 Nonyl-phenoxylpolyethoxylethanol   
ON Over night   
ONC Over night culture   
PBS Phosphate buffered saline   
PE Phycoerythrin   
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1. Introduction 
1.1 The immune system 
The human immune system is a complex and intricate network of cells, organs, 
tissues and their products. Its purpose is to protect the body from invasions of 
pathogenic organisms such as bacteria, helemites, protozoa, fungi and virus. The 
system also protects the body from malignant growths and neoplasia in the form of 
cancer 2. 
The leukocytes and lymphocytes of the immune system originate from the 
hematopoetic stem cells in the bone marrow, from which they migrate through the 
lymphatic system to the peripheral lymph nodes and on to the rest of the body3. Two 
major progenitor lines give rise to the leukocytes of the immune system, the myeloid 
progenitor and the common lymphoid progenitor.  
The myeloid lineage contains most of the cells of the innate immune system, the 
macrophages, dendritic cells, mast cells, eosinophils, neutrophils and basophils. The 
common lymphoid lineage includes all the lymphocytes of the adaptive immune 
system, as well as the natural killer cells (NK-cells)3. 
The immune system itself is characterized by its ability to respond to antigenic 
(antigen from antibody generating) substances. Dependent on the type of antigen, the 
immune response can take multiple forms, involving all parts of the immune system, 
but the ultimate goal of such a response is generally to protect the body from foreign 
substances. The first part of the immune system to respond is generally the innate part 
of the system. The first response is generally at the barriers of skin and mucus, then 
by cells responding to the antigen deeper in the tissues. All these responses are non-
specific. The cells of the innate immune system rely on germ-line encoded pattern-
recognition receptors to distinguish self from non-self, and they are more often than 
not sufficient to remove the pathogen and antigenic substance from the body2. 
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Throughout an innate immune response, pathogens and antigens will be taken up by 
antigen presenting cells of the immune system and transported to draining lymph 
nodes for presentation to the cells of the adaptive immune system. 
 
1.2 The adaptive immune system 
The adaptive immune system is a very specific and efficient system of protection 
against pathogens. While slower to react to new infections than the innate immune 
system, it is able to adapt to specific pathogens and respond with very specific 
antibodies and receptors. It is also able to induce immunity, so that a reinfection of 
the same pathogen will induce an immediate adaptive immune response through 
immunological memory3,4. The adaptive immune system can be divided into humoral 
and cell-mediated immunity. Humoral immunity consists of antibodies and the B-
cells that create them. Cellular immunity covers the CD8+ T-cells and the CD4+ T-
cells2. T-cells develop in the thymus, where they go through positive and negative 
selection for reactions to self-antigens by binding to the MHC-molecules of the 
thymus epithelial cells5. 
The APCs of the innate and adaptive immune system transport antigens to the 
draining lymph nodes in close proximity to the infected tissue. There the antigens are 
presented to the T-cells circulating in the lymphatic system. Antigen specific T-cells 
are retained in the lymph node and are activated to become effector T-cells. B-cells 
that encounter antigens will take them up through B-cell receptor mediate 
endocytosis and present it on MHC class II on the cells surface. These cells will 
migrate to the T-cell area of the lymph node. The activated CD4+ T-cells and B-cells 
that recognize the same antigen will interact and the T-cell will activate the B-cell 
while the B-cell provides further survival signals to the T-cell through a variety of 
interactions3,6. The T-cell/B-cell interaction can be self-replicating from this point on, 
which will perpetuate the immune response outside the lymph node as well7.  
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Figure 1: T-cell/B-cell interaction with T-cell help and B-cell antigen presentation at the initiation of an 
adaptive immune response. Illustration from Edwards and Cambridge, 2004 8 
Both the B- and T-cells will start to multiply and create effector cells. The B-cells 
will congregate into germinal centers and begin to produce a large amount of 
antibodies against the antigen. The effector T-cells will migrate to the infection site, 
and will start recruiting more innate immune cells to start combating the infection, 
including modifying the local cytokine environment, increasing blood flow and 
destroying aberrant or infected cells2,3,9. Once the infection has been eradicated, long 
lived memory B-cells will migrate to the bone marrow and sustain specific immunity 
towards the antigen for many years. A second infection will therefore illicit a very 
swift and specific adaptive immune response facilitated by memory B- and T-cells 
that retain immunological memory of the antigens4.   
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1.3 Antigen presenting cells 
To become active and initiate an adaptive immune response, the naive T-cells need to 
be presented with their specific antigen on the surface of a cell. This is done by use of 
a Major Histocompatibility Complex molecule (MHC). All normal nucleated cells in 
the body express MHC class I proteins on their surface, to present peptides from the 
cells interior to migrating T-cells. The MHC class I molecule is associated with the 
CD8 co-receptor, so that it is the CD8+ T-cells that respond to peptides presented on 
these molecules. This ensures that CD8+ T-cells, who are specialized in killing cells 
infected with intracellular pathogens or are cancerous, are activated to attack the 
infected cells10. 
MHC class II molecules are the focus of this thesis, and will be explored more in the 
next section. They are present mostly on professional antigen presenting cells 
(APCs). These cells are specially equipped to take up and process extra cellular 
antigens and present them to CD4+ T-cells. These T-cells give activation help to B-
cells in the lymph nodes, produce a variety of cytokines and control the development 
of immune responses by developing into specific subclasses11. Professional antigen 
presenting cells consists of dendritic cells, macrophages and B-cells. Of these, 
dendritic cells are by far the most effective, but all of them are capable of taking up 
and presenting antigens12. 
Dendritic cells are divided into three major lineages: follicular, plasmacytoid and 
myeloid dendritic cells. These designations are given from morphology, location and 
function. The follicular cells reside in the lymph nodes, where they seem to work as 
an antigen deposit for activating and stimulating T- and B-cells. The plasmacytoid 
cells wander the blood and lymph, while the myeloid cells migrate to the tissues of 
the body and reside there until they pick up antigen and relocate to draining lymph 
nodes, where they participate in priming the T-cells. Dendritic cells have large 
amounts of MHC class 2 molecules on their surface and are very efficient at T-cell 
priming and activation. They all perform pinocytosis, phagocytosis and receptor 
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mediated endocytose to engulf antigens. The engulfed particles are broken down to 
peptides and presented at MHC class II molecules on the dendritic cell surface. 
Myeloid dendritic cells are often associated with a specific tissue, and immune 
system activations can initially be tissue specific, localized events. Generally, it is the 
tissue specific myeloid dendritic cells that migrate to the lymph nodes and present 
their antigens to T-cells to initiate the adaptive immune response13,14.  
Macrophages are an integral part of the innate immune system, and are effective 
APCs. Their main task is to break down dead cells, pathogens or other refuse in the 
tissues through phagocytosis. Most of the peptides from the phagosomes will be 
presented on the surface of the tissue macrophages, but depending on the local 
cytokine environment and signals the macrophage receive,  this may either prevent or 
escalate inflammatory reactions. Macrophages are also heavily involved in the 
development of organs and the repair of tissue damage, which prevents a limiting 
classification of the macrophage as an immune cell only14,15.  
B-cells are APCs, but have a significantly lower amount of MHC class 2 molecules 
and co-receptors on their surface than dendritic cells. This makes them far less 
effective as APCs, but B-cells have many other functions, most notably the 
production of antibodies. B-cells takes up antigens from the environment both by 
phagocytosis, pinocytosis and receptor mediated endocytosis. Of these, the receptor 
mediated endocytosis is thought to be the most important. The B-cell receptor is 
identical to a membrane bound antibody, and receptor mediated endocytosis through 
the BCR will be specific for that antigen. The BCR mediated endocytosis leads 
directly to the MHC class II loading compartments, facilitating presentation of the B-
cells antigen on its surface. B-cells are able to take up and concentrate small amounts 
of antigen transported to the lymph node or in the blood this way16. The BCRs 
affinity for the antigen is directly proportional to the B-cells ability to induce CD4+ 
T-cell proliferation during B-cell/T-cell interaction17. 
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1.4 MHC class II molecules 
The Major Histocompatibility Complex (MHC) molecules determine much of the 
immune systems capabilities. The name refers to the molecules being encoded in the 
Major Histocompatibility Complex region of chromosome 6 in the genome. In 
humans this region is also called HLA, for Human Leukocyte Antigen. Both terms 
are used in this thesis when talking of the MHC in humans. The MHC region contain 
several different MHC class I and II genes, with multiple variants of each gene 
common in the population, making the MHC region both polygenic and 
polymorphic3,18. Each individual express their MHC genes as haplotypes, a 
combination of alleles encoded on the same chromosome. MHC class I is encoded in 
4 genes, HLA-A, B and C coding for the alpha chain and one gene coding for the β-
chain microglobulin. MHC class II is encoded in 7 genes: DR, DQ and DP genes for 
both an alpha and a beta chain, with DR having 2 beta chain genes instead of one. 
This means that a typical human can produce 6 different MHC class I and 8 MHC 
class II molecules2,18.  
MHC class 1 molecules are present on all cells in the body with a few exceptions. 
They present endogenous peptides produced in the cell to migrating T-cells that can 
recognize the non-self peptides produced by intracellular parasites, virus and 
cancerous cells10. 
MHC class II molecules are the primarily focus of this thesis. Unlike MHC class I, 
MHC class II molecules are present only on antigen presenting cells and some 
epithelial cells. The proteins is used to present extra cellular molecules taken up by 
the APC ,through phagocytosis, endocytosis or pinocytosis, on the APC cell 
surface19. The MHC class II protein is made up of an α-and a β- chain in an non-
covalent complex, each contributing to the peptide binding groove. Each chain has a 
membrane distal and a membrane proximal domain, with the membrane distal 
domains making up the binding groove. The membrane proximal domain is 
transmembrane, anchoring the MHC protein to the cell surface  
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Figure 2: MHC class II ribbon model created in PyMOL (DeLano Scientific), showing HLA-DQ2.5 with α-
chain (black), β-chain (white) and gliadin bound in binding groove (grey). 
MHC class II molecules are synthesized in the rough ER and form a transitory 
aggregate with the chaperone proteins BiP, calnexin, Erp72 and invariant chain. 
These help fold and assemble the MHC class II complex correctly. Invariant chain 
(Ii) is a non-polymorphic transmembrane glycoprotein, but it may vary in length. 
There are 4 common isoforms of Ii expressed in humans, called p33, p35, p41 and 
p43, created by variation in initiation sites and differential splicing during Ii 
translation. The MHC class II complex will collapse without a peptide bound in the 
peptide binding groove, so the Ii binds to the binding groove of the MHC class II 
during formation. This also prevents binding of endogenous intracellular molecules to 
the groove in the ER and Golgi (figure 3). Ii incorporates a variety of sorting signals 
at the N-terminal end that directs the MHC class II molecule into the MHC class II 
loading compartments (MIIC), either from the E.R or after internalization from the 
cell surface20,21,22,23(figure 4). 
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Figure 3: Schematic drawing of the invariant chain interacting with MHC class II, blocking the binding 
groove. Ii(light grey), CLIP (dark grey) and MHC class II (white) showing the progressive degradation of Ii as 
the MHC class II reaches the MIIC compartment.  Picture from Immunobiology, 6ed.l 20053. 
Once the MHC class II molecule enters the MIIC, Ii and the other chaperones are 
degraded, leaving only the class II-associated invariant chain peptide (CLIP) blocking 
the peptide binding site. This peptide is the centre of the invariant chain and the part 
blocking the binding groove. As with the original invariant chain, the CLIP peptide 
can vary slightly in length and residue make up, but is in principle non-polymorphic. 
The CLIP peptide prevents the binding of other peptides to the MHC class II 
molecule until the CLIP is removed. The removal is accomplished by a third MHC 
molecule, which in humans is called HLA-DM. HLA-DM is a protein with the same 
structure as the MHC class II molecule, but it lacks the peptide binding groove. It 
contains a MHC class II interaction area that interacts with an area in the alpha chain 
of the MHC molecule. This interaction catalyzes the release of the CLIP peptide from 
the MHC class II molecule and loading of another peptide into the groove. HLA-DM 
also catalyze removal of weakly binding peptides to the groove and the loading of 
strong binders, thus ensuring that only peptides which bind strongly to the MHC class 
II protein in question can be presented on the cell surface. The deactivation of HLA-
DM causes accumulation of CLIP on the MHC class II both in MIIC and on the cell 
surface24,25,26.  
 
 17
 
Figure 4: Simplified scheme of MHC class II transport to MIIC and presentation of peptide on the cell 
surface, created by Lars-Egil Fallang. 
In addition to HLA-DM, which all APCs contain, B-cells contain HLA-DO. This 
non-classical MHC molecule catalyses the deactivation of HLA-DM at high pH by 
binding to it and preventing interaction with MHC class II16. This is thought to 
facilitate presentation of antigens absorbed through the BCR by the following 
mechanism. Antigens binding to the BCR moves to the MIIC, but do not detach from 
the BCR until the pH becomes low because of the stable interaction between the BCR 
and its antigen. Since HLA-DO prevents CLIP detachment at higher pH, the BCR-
bound antigens will be favored for presentation on the B-cell surface16,26. 
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1.5 MHC class II peptide binding 
The MHC class II binding groove is made up of a “floor” of β-sheets and “walls” of 
α-helices. The binding groove is made up of residues from the membrane distal 
domain of both the α- and β- chain, so that the binding properties of the MHC class II 
molecule is influenced by both chains (figure 5). The binding groove is not closed of 
in each end like the MHC class I, and can accommodate larger peptides and utilize 
other anchor residues than the class I molecule27. 
Peptides bind to MHC class II in an extended conformation. A pattern of hydrogen 
bonds between the peptide backbone and the conserved amino acid side chains 
extend along the length of the binding groove, and this pattern is remarkably 
conserved between all alleles of the MHCs. Since the hydrogen bonds do not involve 
the side chains of the bound peptide, the interaction is sequence independent and so 
explains how a single class II molecule can bind a large number of different peptide 
sequences20. Of the conserved residues responsible for these hydrogen bonds, three 
are asparagines located at α62, α69 and β82 in positions well suited to make 
hydrogen bonds to the carbonyl and amide groups of the peptide backbone. Other 
conserved residues include histidine β81 and tryptophane β61, which are positioned 
to make hydrogen bonds with carbonyls at the P-1 and P-8 positions20,28. This is by 
no means an exhaustive list. There are many such residues able to form hydrogen 
bonds to the right peptide in the groove. 
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Figure 5: MHC class II showing a) protein structure, b) schematic drawing, c) binding groove structure. 
Picture from DeFranco et.al 2007 27 
The binding groove is lined with polymorphic amino-acids that form a series of 
pockets. The side chains of the peptide binding to the MHC class II molecule extend 
into these pockets. Interactions and bonds between the residue forming the pocket 
and the peptide side-chains increase the specificity of the binding groove. In addition, 
a substantial amount of surface area can be buried in these pockets and will then be 
shielded from the solvent, which also increases the specificity of the interaction 
between the MHC groove and the peptide. The side-chains in the peptide binding 
pockets differ between the MHC class II alleles, and this explains the difference in 
peptide binding specificity between them. The pockets are named after the side 
chains they accept, starting with P1 (see figure 8). In practice, most peptides bind 
only to the side chains of a few key anchor residues, but these may vary from allele to 
allele. The most commonly used are P1 and P9, followed by P4 and P6 (figure 6). 
Each allele has a binding motif, and what peptide will bind to the groove can be 
dependent on only a few critical residues20,29. Together, these two mechanisms are 
thought to decide the binding of peptides in the MHC class II binding groove. 
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Figure 6:  Binding of peptides to the murine 
HLA-molecules.  I-Ad, I-Ak and I-Ek murine MHC 
class II molecules in the binding groove (blue). 
Main anchor pockets and residues are shown and 
marked. Carbon, oxygen and nitrogen atoms of 
the bound peptide are also shown. Picture from 
Nelson and Fremont 199920. Note how the 
different peptides interact with different pocket 
residues  
1.6 Celiac disease  
Celiac disease is a chronic inflammatory disorder of the intestine causing 
malabsorption of nutrients and potentially increased mortality and morbidity in 
afflicted patients. It is an acquired disorder that can develop any time, from childhood 
to middle age. Celiac disease is classified as an autoimmune disease, but it has a 
multifactoral cause in the complex interplay of genetic and environmental factors that 
contribute to the pathogenesis. There is no doubt that celiac disease develops by 
intolerance and inappropriate immune response to ingested wheat gluten. Gluten is a 
complex mixture of gliadin and glutenin polypeptides. Of these, gliadins are 
monomers and are thought to be the main environmental factor triggering the 
autoimmunity. Glutenins are larger polymeric structures, and believed to be less 
involved in the development of celiac disease 30.  
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Celiac disease is an uncommonly good model for chronic inflammatory and 
autoimmune diseases, since both the environmental factor and the disease associated 
HLA-genes are know. In addition, gluten is relatively easy to add or withhold in an 
experimental system, and the affected organ is easily accessible for biopsy and study. 
 
Figure 7: Gut epithelial histology from a) normal and b) celiac small intestine. Histology shows the villi (v) 
and crypts. In b) the lamina propria (LP) has swelled out, the villi has atrophied and there is an extensive 
lymphocyte infiltration evident (black dots). Picture from Sollid 2002 30. 
Celiac disease is a genetic disorder, with a 75% concordance rate between twins31. 
HLA-linked genes contribute a large amount to the genetic susceptibility, but 
dependent on the model used for the disease non-HLA linked genes may play a larger 
role. In this thesis, the concern is primarily with the HLA-linked genes. The HLA 
association in most celiac patients is with DQ2 (DQA1*05/DQB1*02), with a 
minority associated with DQ8 (DQA1*0301/DQB1*0302) instead. Most patients 
have the DR3-DQ2 haplotype (DRB1*0301-DQA1*0501-DQB1*0201) or are DR5-
DQ7 and DR7-DQ2 heterozygote (DRB1*11/12-DQa1*0505-DQB1*0501 and 
DRB*07-DQA1*0201-DQB1*0202) 32(figure 8). These DQ molecules are also 
associated with other autoimmune diseases, for instance insulin dependent diabetes 
mellitus33, which establishes a broader basis for the study of these  MHC class II 
haplotypes in particular and MHC class II molecular binding mechanisms in general. 
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The HLA-DQ2 and DQ8 molecules are assumed to present gluten peptides to T-cells 
in the gut, explaining their association with the disease. Both the HLAs have 
preference for negatively charged peptides in the peptide backbone, but gluten 
peptides contain relatively few negative charges. This conundrum is solved by tissue 
transglutaminase 2 (TG2), a deaminating enzyme that is also the predominant auto-
antigen in celiac disease. The enzyme catalyzes transamidation of peptides, and is 
also the prevalent autoantigen in celiac patients34,35.This way the enzyme introduces 
negative charges into the gluten peptides in situ and makes them adequate binders to 
DQ2/DQ8 HLA. The presence of proline at crucial areas of the peptide normally 
hinders binding to HLAs, with the exception of promoting PPII helix structures. DQ2 
and DQ8 allow for proline more readily than most other HLA molecules and are 
favored for binding proline rich peptides compared to other HLAs. It is known that 
gluten peptides are often unusually proline rich36, and it is postulated that the lack of 
a residue in position α53 is the cause of the preference for proline in the position 
normally making a hydrogen bond to that residue. 
 
Figure 8:  HLA-DQ2.5 germ line encoding. HLA-DQ2.5 can be encoded in 3 different haplotypes, either in 
cis or trans, combining to make the complete HLA-DQ2.5 protein after translation. As can be seen, A05 and 
B02 can be combined to a molecule in both haplotypes. Figure from Sollid 2002 30 
DQ2 has two major variants, HLA-DQ2.2 and HLA-DQ2.5. Only HLA.DQ2.5 is 
associated with celiac disease to any degree, with HLA-DQ2.2 only being present in 
a negligible amount of cases. Their β-chain differs in only one amino acid in the 
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membrane proximal region and has no influence on peptide binding. The alpha-
chains (DQA1*0202 and DQA01*0205) have a 10 polymorphic residues in the 
membrane distal domain, as well as 6 polymorphisms in the membrane proximal 
domain. 4 of the membrane distal polymorphisms are located around the antigen 
binding area, while the remaining 6 may be located in the presumed HLA-DM 
interaction area of the MHC class II molecules 25 (figure 9). Only the membrane 
distal polymorphisms interact with the bound peptide, and these are therefore the 
major points of interest when considering the difference between the two alleles. 
α-chain
β-chain
R49H
Q31E
G37E
L48F
C44KV47L
Q50R
F51L
S71I
Y22F
 
Figure 9: HLA-DQ2.5 polymorphic sites. HLA-DQ2.5 is shown with the peptide backbone in the binding 
groove and hydrogen bonds in dashed lines. Target polymorphisms from HLA-DQ2.5 to HLA-DQ2.2 are 
marked. Figure modified from Kim.et.al37. 
It has been shown that DQ2.5 has fairly unusual antigen binding properties, retaining 
large amounts of CLIP on the cell surface. HLA-DQ2.5 has been shown to be a poor 
substrate for HLA-DM38, and as 6 of the polymorphisms are located in the presumed 
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HLA-DM interaction region, that might be part of the answer. Early results from 
studies done at the Sollid group indicated that the polymorphisms around the binding 
groove are more important, especially since it has been indicated that HLA-DQ2.2 is 
also an equally poor DM substrate1. The prime target for finding the amino acids 
responsible for these differences in the binding properties of the DQ2.2 and DQ2.5 
are therefore the 4 variable amino acids clustered around the antigen binding groove 
more than the 6 amino acids clustered in the HLA-DM interaction area.  
 
Table 1: CLIP-peptides commonly eluted from HLA-DQ2.538 
CLIP peptide Sequence Length Mass 
Ii81–104 LPKPPKPVSKMRMATPLLMQALPM 24 2674. 5 
Ii81–103 LPKPPKPVSKMRMATPLLMQALP 23 2543.4 
Ii82–103 PKPPKPVSKMRMATPLLMQALP 22 2430.4 
Ii81–101 LPKPPKPVSKMRMATPLLMQA 21 2333.3 
Ii93–109 MATPLLMQALPMGALPQ 17 1781. 9 
Ii93–108 MATPLLMQALPMGALP 16 1653. 9 
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1.7 Aim of thesis 
The aim of this thesis is to investigate which of the 10 membrane distal 
polymorphisms in HLA-DQ2.5 and HLA-DQ2.2 may explain the differences seen in 
CLIP presentation by the two molecules. The results may also help explain part of the 
celiac disease association differences between them. Site directed mutagenesis of the 
HLA-DQ2 genes will be used to introduce one polymorphic residue from HLA-
DQ2.2 into the corresponding site in HLA-DQ2.5. By eluting and analyzing the CLIP 
peptides presented by the mutant EBV-transformed B-cells on mutated HLA-DQ2.5 
molecules, differences in CLIP presentation can be measured. A difference in the 
level of CLIP presentation may indicate differences in CLIP stability in the binding 
groove. If such a difference is observed, the reverse mutation will be attempted by 
introducing the polymorphic residue from HLA-DQ2.5 into HLA-DQ2.2. The 
opposite effect on the level CLIP presentation of the HLA-DQ2.2 mutant will 
confirm the importance of the residue in terms of CLIP stability in the binding groove 
of HLA-DQ2. 
This thesis work is a part of a study by the Sollid group at the Centre for Immune 
Regulation, Oslo, and will focus only on 3 of the 10 polymorphic residues. The 
polymorphic residues in position α31, α37 and α72 were chosen as the ones to focus 
on in this thesis work. 
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2. Methods and materials 
When nothing else is  indicated, all solutions and methods mentioned below were 
done in accordance with the protocols found in Sambrook39.  
2.1 PCR and creation of the target gene with a 
transmembrane tail 
Reagents 
cDNA encoding HLA-DQA01*0201(from B-LCL 9047 PLH), HLA-DQA1*0501 
and DQB1*0201(from B-LCL CD114), Phusion DNA polymerase (NEB), High 
Fidelity Buffer (NEB), 10 mM dNTP (NEB)  
20X TBE: 216 g Trisma base (Sigma), 110 g boric acid (Merck), 18.6 g 
EDTA(triplex III) (Sigma), MQ water  for total volume 1L 
Agarose gel: 1% agarose (Merck), 50 ml 1X TBE, 5 μl ZyberSafe (Promega)  
Primers 
Table 2: PCR primers, from the Celiac Group, Centre for Immune Regulation 
Primer 1 TGGGAAGCTTATGATCCTAAACAAAGCTCTG 
Primer 2 GGATAAGCTTCACAAGGGCCCTTGGTGTC 
Primer 3 CCAGCCCCTATGTCAGAGCTCACAGAG 
TM-tail 
megaprimer 
CCAGCCCCTATGTCAGAGCTCACAGAGACTGTGGT 
CTGCGCCCTGGGATTGTCTGTGGGCCTCGTGGGCAT 
TGTGGTGGGCACTGTCTTCATCATCCGAGGCCTGCG 
TTCAGTTGGTGCTTCCAGACACCAAGGGCCCTTGTGTC 
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The HLA-DQA1*0501 and HLA-DQA1*0201 genes studied in this thesis were 
earlier created by cDNA synthesis from a B-cells line graciously given to the Sollid 
group by B.Roep. The plasmids created with this cDNA contain the HLA-genes 
modified with a leucin-zipper soluble tail, and this must be replaced with the native 
trans-membrane tail before mutagenesis and retroviral transduction can be done. The 
TM-tail was already encoded in a pLHCX a different construct.  The encoded trans-
membrane domain needed to be lifted out of the construct by use of PCR 
(Polymerase Chain reaction), in vitro amplification of DNA through use of a heat-
stable DNA polymerase and a programmable heat-block as described by Mullis 
et.al.40 and by Sambrook et.al39.  All PCRs were done on a Veriti 96-well Thermal 
Cycler (Applied Biosytems). The sequence of all primers used is shown in table 2. 
PCR mix: 5 μl HF buffer, 15.5 μl MQ water, 1 μl construct pLHCX construct with 
TM-tail, 10 nM primer 2, 10 nM primer 3, 1 μl dNTP, 0.5 μl Phusion enzyme. 
PCR-program: Hold (1): 98° -30 s., Melt (2): 98° - 10 s, Anneal (3): 57° -10 s, 
Elongation (4): 72° - 10 s, End (5): 72° - 5 min, 30 cycles 
The resulting 145bp DNA fragment was purified on a 1% agarose gel, then used as a 
megaprimer for the PCR of the target gene (HLA-DQA1*0501/HLA-DQA1*0201), 
the forward primer being primer 1. These primers introduced HindIII restriction sites 
in the gene. PCR-program: Hold (1): 98° -30 s., Melt (2): 98° - 10 s, Anneal (3): 57° -
15 s, Elongation (4): 72° - 20 s, End (5): 72° - 5 min, 30 cycles. 
The PCR-product was treated with HindIII restriction enzyme and ligated into the 
pMOS mutagenesis vector in accordance with protocol described in 3.5. 
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2.2 Ligation of gene into cloning- and expression vector 
Reagents 
pLHCX expression vector (Clonetech), pMOS Blue cloning vector (GE Healthcare 
Life Sciences, cDNA encoding HLA-DQA01*0201(from B-LCL 9047 PLH), HLA-
DQA1*0501 and DQB1*0201(from B-LCL CD114), T4 ligase (NEB), T4 ligase 
buffer (NEB). 
pLHCX
6812 bp
5 LTR
3' LTR
Hygromycin res
AmpR
CMV IE promoter
extended packaging signal
H indIII (36 58)
SacI (4 14 )
SacI (284 2)
SacI (356 4 )
SacI (4132)
AvaII (26 1)
AvaII (274 )
AvaII (329 )
AvaII (627)
AvaII (757)
AvaII (1286)
AvaII (19 28)
AvaII (24 69 )
AvaII (2737)
AvaII (36 33)
AvaII (3980)
AvaII (39 9 3)
AvaII (4 04 8)
AvaII (4 34 5)
AvaII (5815)
AvaII (6 037)
 
Figure 10: pLHCX expression vector (Vector NTI) 
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Figure 11: pMOS-blue cloning vector, multiple cloning site shown in the lacZ region. Ampicilin resistance 
shown as Ap. 
T4 ligase(NEB) was used for ligation of the target genes into cloning- and  
expression vectors, using the commercial available protocol41. The target genes, 
produced with TM-tail as described in 3.1 and target vectors were cut with HindIII, 
purified on an agarose gel (3.4) and ligated with the target gene as described in the 
NEB protocol.  
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2.3 TOPO-cloning of target gene 
Reagents 
TOPO-cloning kit (Invitrogen) 
pCR2.1-TOPO
3931 bp
Amp(R)Kan(R)
M13 (-20) forward primer
M13 (-40) forward primer
M13 reverse primer
T7 primer
Kan promoter
lac promoter
T7 promoter
lac repressor binding site
TOPO binding siteTOPO binding site
f1 origin
pUC origin3'-T overhang 3'-T overhang
Sac I (3888)
Hin dIII (3872)
 
Figure 12: pCR2.1-TOPO cloning vector (linear). The target gene is inserted between the two terminal 3’T 
overhangs, creating a circular plasmid. 
TOPO-cloning was done as described in the commercial TOPO-cloning kit 
protocol(Invitrogen)42. This is a commonly used TOPO cloning kit, containing a 
linearized plasmid (pCR2.1) coupled with topoisomerase for swift ligation of an 
adenine flanked DNA fragment into the linearized plasmid. TOPO cloning was done 
to create the pCR2.1 plasmid with HLA-DQA1*0501 since some of the HLA-
DQA05 mutagenesis primers, notably primer 5 (see table 3), seemed at one point to 
anneal at non-target sites in the pMOS plasmid, creating unspecific mutations. 
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2.4 Transformation of XL-1 bacteria 
Reagents 
 SOC-media: 950 ml MQ water, 20 g bacto-trypton (Merck), 5 g bacto-yeast extract 
(Merck) 0.5 g NaCl (Merck), 250 mM KCL (Sigma), 5 ml 2 M MgCl2 (Sigma), 20 ml 
1 M glucose (Merck). 
LB-media: 950 ml MQ water, 10 g Bacto-trypton (Merck), 5 g Bacto-yeast extract 
(Merck), 10 g NaCl (Merck) 
LB-agar: 1 L LB-media, 15 g Bacto-agar (Bectin, Dickinson and Company)  
 
80μl XL-1 E.coli bacteria was thawed on ice and approx. 300 ng of the vector 
plasmid was added, then incubated 30 min. on ice, 45 s at 42°C and a further 2 
min.on ice. 120 μl SOC media was added to the bacteria and the mix was incubated 
with shaking at 37°C for 1h. Streaked out on a LB-agar plate with ampicillin (50 
μg/ml) and incubated at 37°C ON. 
Overnight cultures were created by picking a single colony and suspending it in 3ml 
LB media/ampicillin (50 μg/ml). The cultures were placed at 37°C in an incubator 
ON. 
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2.5 DNA-isolation and gel electrophoresis 
Reagents 
Wizard Miniprep Kit (Promega), Plasmid Midikit (Qiagen), Qiaquick Gel Extraction 
kit (Qiagen), NEBuffer 1-4 (NEB), HindIII(NEB), SacI(NEB), BglII(NEB), 
AvaI(NEB), 1x Loading Buffer (Promega), Isopropanol (Arcus Kjemi), 100% 
Ethanol (Arcus Kjemi) 
20X TBE: 216 g Trisma base (Sigma), 110 g boric acid (Merck), 18.6 g 
EDTA(triplex III), MQ water for total volume 1L 
Agarose gel: 1% agarose (Merck), 50 ml 1X TBE, 5 μl ZyberSafe (Promega)  
 
Wizard Miniprep (Promega)43 and Plasmid Midikit (Qiagen)44 were used to isolate 
the DNA from the transformed bacteria grown in ONCs, as described in their 
respective commercial protocols. The miniprep. kit is a standard kit used by a large 
amount of research laboratories at the University of Oslo, regularly giving a DNA 
concentration of 50-150 ng/μl  when eluted according to protocol. To control the size 
and identity of plasmids, and to isolate particular genes from a plasmid, specific 
restriction enzymes were used to cut out the gene and/or cut the plasmid into linear 
pieces and analyze them on an agarose gel as described in the commercial protocol 
(NEB)45. Hind III and SacI were used for such control of the pMOS and pLHCX 
vectors with DQA gene inserts. 
50 ml 1% agarose TBE/5μl ZyberSafe gels were used for gel electrophoresis in a 
plastic electrophoresis chamber. DNA was applied with 1x Loading Buffer 
(Promega). Standard running time was 40 min at 80V in TBE-buffer. An UV-gel-
dock was used to record and identify bands for analysis or DNA gel extraction 
described. To remove the DNA from the gel after electrophoresis, the Qiaquick Gel 
extraction kit (Promega ) was used, as described in the commercial protocol46.  
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2.6 Site-directed mutagenesis 
Reagents 
Quikchange Multi-site Mutagenesis kit (Stratagene) 
Primers 
Table 3: Mutagenesis primers, synthesized at Eurogentech S.A.  All mutagenesis primers are phosphorylated 
at the 5’end. Each primer introduces a specific mutation by a single nucleotide exchange, the target nucleotide 
is marked by a frame. The mutations has been named in the table  as follows: Original residue, residue 
position, mutated residue, followed by which DQ2 variant the mutation is to be introduced in. Primer 4 is 
marked Sα72I, DQ2.5, and introduces the mutation serine to isoleucine in position 72 of the HLA-DQ2.5 alpha 
chain. 
Primer 4 (mutation Sα72I, DQ2.5) ctaaaacataacttgaacattctgattaaacgctccaac 
Primer 5 (mutation Qα31E, DQ2.5) gatggagatgaggagttctacgtggacc 
Primer 6 (mutation Gα37E,DQ2.5) ctacgtggacctggagaggaaggagactg 
Primer 7 (mutation Iα72S,DQ2.2) ctaaaacataacttgaacagcctgattaaacgctccaac
Primer 8 (mutation Eα31Q,DQ2.2) gatggagacgagcagttctatgtggacctg 
Primer 9 (mutation Eα37G,DQ2.2) ctatgtggacctggggaggaaggagactg 
 
Site-directed mutagenesis in vitro is a commonly used technique to introduce specific 
mutations in a target gene. Several approaches are possible, but many include 
cumbersome use of single-stranded DNA templates and subcloning in a M13-based 
bacterial vector. The Quikchange Multi-site Mutagenesis Kit (Stratagene)47 avoids 
many of these problems, and was therefore chosen for the mutagenesis reaction. 
Using the Multi-site kit compared to a standard site-directed kit allows the kit to be 
used with only one mutagenesis primer for each mutation. Primers with the required 
mutations were designed by using an online tool to calculate Tm. at 
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(www.stratagene.com). The mutagenesis process is in principle a normal PCR with a 
primer including the mutated base(s). As template the pMOS-DQA105, pMOS-
DQA10201 and pCR2.1 DQA105 plasmids created earlier were used. After the PCR, 
the PCR-products will incorporate the mutation, as seen below. 
 
Figure 13: Site-directed mutagenesis,  illustration from the Stratagene Mutagenesis kit 47. Step 1 shows how 
the mutagenesis primers anneal and extends the plasmid, creating a copied plasmid that includes the mutation. 
As the PCR reaction continues, all copies of the original plasmid will include the mutation. Step 2 shows Dpn1 
restriction enzyme digestion that removes the non-replicated DNA, which is methylated and not mutated. Step 
3 shows the finished plasmid with mutations included, ready for transformation into XL-1 bacterial cells.  
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2.7 Sequencing 
Sequencing of the mutations in cloning vectors and expression vectors were done at 
GATC Biotech in Cologne, Germany, according to their own protocols. 
 
2.8 Cell maintenance 
Reagents 
721.82 EBV transformed B-cell line from B.Roep, GP2-293 cells (Clontech, 
#641530), DMEM with Na/Pyruvate(Invitrogen), dPBS (Invitrogen), PBS 
(Invitrogen), Fetal Calf Serum(FCS)(Cambrex), Penicillin (Panpharma), 
Streptomycin (X-gen Pharmaceuticals), Neomycin (Invitrogen), 1M 1X Hepes 
(Invitrogen), Trypsin 0,5% EDTA (Invitrogen) 
RMPI complete media: 500 ml RMPI 1640(Invitrogen), 10% FCS (Cambrex), 1M 
1X Hepes(Invitrogen),  
All cell flasks and dishes were grown in a 37 °C, 5% CO2 cell incubator if nothing 
else is noted. 
The 721.82 B-cell line is EBV transformed to survive in suspension in vitro. The 
particular line used here has also been retroviraly transduced with a plasmid coding 
for the DQ2 β-chain and resistance against neomycin. A single tube containing 
approx. 5*106 cells were thawed and suspended in 20 ml RPMI complete media and 
1.0 μg/ml neuomycin. The cells were split when confluent, usually every third day, 
by exchanging 90% of the medium with fresh medium. 
The GP2-293 cells are part of the Retroviral Universal Packaging System, batch 
631530, from Clonetech. Liquid nitrogen stock was thawed and transferred to T-75 
flask (NUNC) with 20 ml DMEM (Invitrogen) and 10% FCS.  The cells are adherent 
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and became confluent after about 72 hours. The cells were split 1/12 by removing the 
old media, washing with 5 ml PBS, then adding 3 ml trypsin to detach the cells. The 
cells were suspended and centrifuged at 800rpm for 5 min. The cells were 
resuspended again in 11 ml fresh media for a 1/12 split, and placed back in the 
incubator. 
2.9 Transfection of GP2-293 cells 
Reagents 
 GP2-293 cells (Clontech, #641530), DMEM with Na/Pyruvate(Invitrogen), PBS 
(Invitrogen), Fetal Calf Serum(Cambrex), Trypsin 0.5% EDTA (Invitrogen), Poly-L-
Lysine (Sigma), Optimem (Invitrogen), Lipofectamin 2000(Invitrogen), pAMPHO 
plasmid (Clonetech). 
 
The line of EBV transfected B-cells used in these experiments is not transfectable 
directly by lipofectamin or other methods. As such, the target gene must be 
transfected into GP2-293 kidney cells, provided by Clonetech as part of their Retro 
Viral Universal Packaging system48, and using a pAMPHO plasmid which code for 
the viral envelope as a co-transfectant. These cells can then stably express the viral 
coat proteins gag and pol.  
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Figure 14: GP2-293 transfection system illustrated, modified from an illustration by Anna Hayman. 
GAG,POL  and ENV are viral molecules expressed in the cell that forms the viral capsule for further retroviral 
transduction. Note the packaging signal ψ, directing packing of the target genes instead of the instead of the 
viral DNA.  
 
The transfected cells produce virus containing the co-transfected DNA and can then 
be used to co-culture with 721.82 B-lymphocytes previously infected with the gene 
coding for the β-chain. The 721.82 cell line has the HLA-DQ and DR region deleted 
from the genome, and so cannot produce HLA-molecules except the ones coded in 
the DNA introduced by viral transduction. The viral coat will allow the HLA alpha 
chain DNA to transduce the B-cells thus introducing the required gene for the alpha 
chain of the MHC class II molecule, as well as hygromycin resistance to allow for 
selection of the successfully transduced cells. This accomplishes a transduction by 
use of a viral vector. The following protocol is the only established one for this kind 
of viral transduction into B-cells, and is a modified version of the Clonetech protocol 
48 by Anna Hayman, after principles explained in Morgenstern49 and Sekine50 
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10cm diameter dishes were coated with 1:10 diluted poly-l-lysine for 5 minutes to 
prevent the adherent cells from detaching during transfection, and the dishes was 
washed three times with PBS. Using cells maintained as described in 2.8, 1 confluent 
flask of GP2-293 cells for every 3 transduction reaction (including 1 negative control 
for every 3 transductions) were trypsinated (3 ml trypsin 0.5% EDTA) and washed 
with PBS . Detached cells were suspended in 8 ml 10%FCS DMEM, spun down for 
5min at 800 rpm, then resuspended to a concentration of 4.5*105 cells/ml. 10 ml of 
suspension added to each dish, incubate ON until 90% confluent, then the media was 
exchanged to 2%FCS DMEM. 
Transfection DNA dilution was done using 10 μg pAMPHO and 10 μg pLHCX 
expression vector with target gene inserted, mixed with 1.5 ml Optimem for each 
transfection reaction. A lipofectamin transfection solution for each transfection was 
created by incubating 50 μl Lipofectamin 2000 with 1.5 ml Optimem for 5 min, then 
mixing the DNA solutions with the transfection solutions. Note that the negative 
control mix contains lipofectamin and pAMPHO, but no pLHCX plasmid. After 
20min incubation, the lipofectamin/DNA mixture were added drop-wise to the GP2-
293 cells, one mix to each dish, and then placed in the incubator.  
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2.10 Retroviral transduction of 721.82 B-cells in co-culture 
with GP2-293 cells 
Reagents: 
721.82 EBV transformed B-cell line, from B.Roep, Fetal Calf Serum (Cambrex), 
Penicillin (Panpharma), Streptomycin (X-gen Pharmaceuticals), Hygromycin 
(Invitrogen), 1M HEPES (Invitrogen) 
RMPI complete media: 500ml RMPI 1640(Invitrogen), 10% FCS (Cambrex), 1M 
Hepes(Invitrogen), Penicillin (Panpharma), Streptomycin (X-gen Pharmaceuticals). 
 
24h post-transfection, the transfected GP2-293 cells were irradiated with 12Gy. The 
target 721.82 EBV-transformed B-cells (described in 2.8) for co-culture retroviral 
transduction were spun down and resuspended in 50 % used, 50 % fresh complete 
RMPI media to a concentration of 2.5*105 cells/ml. The 2 % DMEM media of the 
irradiated GP2-293 cells were discarded, and 8 ml (2*106 cells in total) were added to 
each irradiated GP2-293 dish, and incubated for 48 h at 37°C. 
After incubation, the dishes were sprayed with a Gibson pipette to detach the GP2-
293 cells, then the cells and media from each dish was transferred to a T-25 flask 
(NUNC). Each dish was washed with 3 ml complete RPMI media, and then added to 
the same T-25 flasks. After another 24 h of incubation, the cells were spun at 700rpm 
for 5 min, the media discarded, then resuspended in 8ml complete RMPI media with 
0.05mg/ml hygromycin selection antibiotics. The cells were returned to the incubator 
for another 72 h and then spun as above and resuspended in 8 ml complete RMPI 
with 0.1 mg/ml hygromycin. The retroviral transduction was now complete, and the 
pLHCX vector was translated into DQ2-alpha chains and hygromycin resistance 
inducing proteins. The efficiency of the retroviral transduction is low, so a majority 
of B-cells will not survive even the mild selection pressure of 0.1 mg/ml hygromycin. 
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The negative control was used to indicate when the majority of the unsuccessful 
transductions were dead. Once the transduced cells started to grow, often as much as 
14 days after end of co-culture, they were transferred to larger T-75 flasks and 
expanded. The selection pressure was then increased to 0.3 mg/ml hygromycin to 
ensure higher levels of DQ2 expression. 
 
 
Figure 15: Retroviral transduction of 721.82 B-cells. GP2-292 cells transfected with HLA-DQ2A*0501 
producing viral capsules for transduction into the B-cells already transduced with the β-chain, which results in 
production of HLA-DQ2 shown on the surface of a 721.82 cell. Illustration  modified from an illustration by 
Anna Hayman.    
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2.11 Flow cytometry of transduced B-cells expressing DQ2 
Reagents: 
Rabbit Anti-Human HLA-DQ2 PE labeled antibody (Diatec) , CerCLIP Rabbit Anti-
Human CLIP FITC labeled antibody (BD Pharmingen), PBS (Invitrogen), Fetal Calf 
Serum (Cambrex) 
 
Cytometry is a process in which the chemical and/or physical properties of a single 
cell are measured. By extension, flow cytometry is a method where such 
measurements are done while the cells flow through a measurement apparatus. A 
suspension of cells is passed through a laser beam, and the refraction from the cells is 
measured in detector channels51. 
3 attributes of the cells can be measured by light scatter flow cytometry: size (forward 
scatter), relative complexity or granularity (side scatter), relative intensity of 
fluorescence.  Forward scatter is a measured by looking at the scattering (angle and 
amount) in a forward direction. Forward scattering is dependent on the surface area 
of the cell, and the amount and the angle of forward scattering depends on the cell 
size. Side scatter measures granularity or complexity of the cell by measuring the 
amount of light that is scattered to the side of the cell when hitting an internal granule 
or organelle in the cell and not continuing on through the cell to hit the forward 
detector.  
Relative fluorescence is detected by channels FL1-4, dependent on the cytometer. 
Each channel can detect only one specific wavelength of fluorescence. In these 
experiments, using the FACSCalibur instrument (BD), both the FL1 and FL2 
channels was utilized, capable of generating and detecting fluorescence from FITC 
(530nm) and PE (585nm) labels51. Fluorescence intensity is a measurement of how 
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many antibodies with conjugated fluorochromes are attached to each cell, and can 
thus be used to measure the expression of a given protein on that cell. 
Both antibodies were used to mark each cell, selecting the population expressing 
HLA-DQ2 with CLIP bound on the cell surface. Compensation for cross reaction 
between the two antibodies was done before the measurements were started. 
 
Gating and compensation 
Gating establishes which of the cells in a population needs to be analyzed, and which 
cells should be ignored. Given the high amount of selection pressure the retroviraly 
transduced cells are under, a large population of dead cells will be present in the 
samples. These were gated out by selecting a gate that includes cells with low SSC 
and relatively high FSC, which is the live lymphocyte population. Compensation for 
cross reactions of the anti-bodies was done by using controls marked only with one 
anti-body. 
Approx. 105 cells were used in each sample for the flow cytometry, and added to a 
well in a 96-well plate. Non-transduced 721.82 cells were included as an isotype 
control for gating, and two wells for each of transfected 721.82 that express DQ2.5 
were included for antibody compensation. The cells were washed by spinning the 
plates 3X 3 min, 1500rpm , 4 °C, and flicked to remove the liquid between each 
centrifugation. The cells were resupended in 200 μl 3 % FCS dPBS. 1:10 suspensions 
in 3 % FCS PBS of the anti-DQ-PE and anti-CLIP-FITC antibodies were created, 
then 50 μl of each were added to each well. Two wells were only mixed with one 
antibody each, for antibody compensation. The plate was then incubated in the dark 
for 30 min on ice. After incubation, the cells were washed twice as described above, 
leaving each well with 200 μl 3 % FCS dPBS cell suspension. Each cell should now 
be marked with anti-CLIP antibodies sending a FITC signal and anti-DQ antibodies 
sending a PE signal. The intensity of these signals will show the amount of each 
molecule present on the cell surface. 
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Analysis of the cells was done at a FACSCalibur flow cytometer using CellQuest Pro 
software suite and WinMDI according to standard operating procedures (BD 
Bioscience). Graphs and statistical analysis was done using GraphPad (Microsoft). 
 
2.12 Protein extraction and purification of MHC class II 
molecules 
Reagents 
Sepharose CL-4B(GE Healthcare), Protein A-sepharose CL-4B (GE Healthcare), 
PBS (Invitrogen), Sodium azide(Sigma), NP-40(Sigma), Citrate, (Sigma), 2.7μm 
filter (GE Healthcare Whatman) , 0.7  μm filters (GE Healthcare Whatman), 0.4 μm 
filters (Millipore), Octylglycoside (Calbiochem), Saturated HCl (Merck), Trisma 
Base (Sigma) 
2X Lysis Buffer: 10 mM Na-orthovandate (Sigma), 50 mM Iodoacetamide (Sigma), 
2% NP-40, 2 mM 17.4 μl/ml PMSF serine protease inhibitor (Roche), 15 ml 0.5% 
Azide PBS 
Blind Elution Buffer 1:0.1 M acetate (Sigma), 0.5 M NaCl, calibrate to pH 4, filtered 
Blind Elution Buffer 2: 0.05 M diethylen (Sigma), 0.15 M NaOH(Sigma) , 0.02 % 
Azide, calibrate to pH11, filtered 
Elution Buffer: 0.05 M diethylen, 0.15 M NaOH, 0.02 % Azide ,1 % Octylglycoside 
(Calbiochem) calibrate to pH 11, filtered 
Neutralizing Buffer: 2 M Tris HCl (Sigma), pH 6.3, filtered 
 
To prepare samples for the MALDI-TOF MS,  approx.0.5*109 cells from each 
retroviral transduction harvested and washed twice with PBS by centrifugation for 20 
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min at 2200 rpm,. The cells were then resuspended in 50 ml PBS, spun again and 
frozen at -70°C as a pellet until 1.5*109 cells was harvested from each transduction 
culture. The cell pellets were resuspended in 15 ml PBS/azide and incubated on ice 
with periodical mixing for 30min. The suspended cells were centrifuged 2x25 min at 
2800rpm to retrieve the supernatant with the peptides, discarding the precipitate. The 
supernatant was filtered through a succession of 2.7μm, 0.7 μm and finally 0.45 μm 
filters using water driven vacuum. 
The collected lysates from each transduced B-cell culture were run through a 
prewashed (150 ml PBS/ 0.05% NP-40) column series to capture and purify the MHC 
class 2 molecules: i: Sepharose CL-3B column, ii: Protein A-sepharose CL4B 
column, iii: 2.12.E11 rabbit anti-human HLA DQ2 coated-Protein A- sepharose 
CL4B column created at the Sollid group. The lysate was added at a rate of 2 drops/s, 
until it had all go onto the columns.  
The columns were washed with 50 ml PBS/0.5%NP-40, NP-40 to prevent 
denaturation of the bound peptides.  The protein A column was washed with 50 ml, 
0.1M citrate buffer (pH 3) and 25 ml PBS/Az/0.5 % NP-40, then 200 ml PBS/Az. 
The anti-DQ2 column was washed with 50 ml PBS/0.0% NP-40/Az then with 500 ml 
PBS/0.1 % SDS/0.5 % NP-40/Az ON, then 50 ml PBS/0.5 % NP-40/Azide, followed 
by 45ml PBS/0.5% octylglycoside/Az. 
Elution of the peptides from columns was accomplished with 25 ml elution buffer 
(pH11.5) directly into 3 ml of neutralization buffer(pH 6.3) 
All the columns were washed with 25 ml PBS/0.5 % NP-40/Az. before blind-eluting 
the columns with 50 ml blind elution buffer 2, followed by PBS, blind elution buffer 
1, PBS,  blind elution buffer 2 and finally 200 ml PBS/0.5 % NP-40/Azide. to prepare 
the columns for the next elution. The eluted DQ2 was then concentrated using 
Vivaspin 20 MW10000 PES concentration columns (Satorius Stedim Biotech), 
3000rpm at 4°C down to 500μl, then washed 2x with 10ml PBS/Az./0.5% 
octylglucoside and centrifuged down to 100 μl. The concentration of the peptides was 
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measured using a BCA Protein Concentration Kit(BIO-RAD) and a Victor3 Multi-
counter spectrophotometer. 
2.13 Elution of peptides from MHC class II 
Reagents 
TFA (Sigma), MQ water, 10,000MWCO Microcon filters (Micon) 
µg of each of the mutants and wt HLA-DQ2 molecules were used for this. The HLA-
DQ2 molecules were added to a 10,000MWCO Microcon filter (Micon), prewashed 
with 2x500µl MQ water. The filters were then washed through twice with 500µl MQ 
water, then acid eluted with 75µl 0.5% TFA, pH 2 for 30 min at 37°C. The filters 
were then spun dry and the filtrate collected. 
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2.14 Mass spectrometry 
Reagents 
TFA (Sigma), αCN matrix (Sigma), reversed phased C18 column material (Sigma), 
R2 column material solution (Sigma)   
 
The basic principles of mass spectrometry are relatively simple. The spectrometer 
performs 3 functions: it vaporizes the sample compound, produces ions from the 
resulting gas-phase molecules and then separates these ions according to mass. When 
producing the gas-phase, the spectrometer invariably shatters the molecule that is 
being looked out into more than one charged ion 52. 
There are many different ways to conduct mass spectrometry, and they are chiefly 
different in vaporization and mass-measurement technology. The powerful MALDI-
TOF technique, which relies on matrix-assisted laser description (MALDI) for 
vaporization and time-of-flight (TOF) measurement for mass calculation, is often 
used when dealing with large biomolecules like peptides and proteins as in this thesis. 
Matrix-assisted laser desorption uses a nitrogen laser to rapidly sublimate a matrix 
crystal and the analyte into gas-phase. In the gas-phase proton transfer reactions 
create charged ions of the peptides, nearly always mono-charged, so there is a 1 to 1 
ratio between charge and mass for the analysis53. Time-of-flight is measured to 
calculate the mass of the fragments. Given a constant acceleration voltage, the flight 
time of a given molecule though the spectrometer is a function of its mass (m)/charge 
(z). For this to be accurate, the flight path needs to be extensive, often incorporation 
ion-mirrors that also calibrate the acceleration of the molecules to minimize variables 
other than m/z. The size of the peptides can then be calculated based on the final TOF 
53. From the size of the peptide fragments measured, it can be deduced which peptides 
and proteins are present in the sample, to a degree. The size of the CLIP peptides 
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bound to MHC class II are known, and so sequencing though MS was not needed. 
The general shape a typical and atypical MS specter eluted from MHC class II is also 
know, and can be compared with the results from the MALDI-TOF analysis. 
The eluted peptides were applied to a ground steel MALDI MS-plate. A Gel-loader 
peptide tip is plugged with a small amount of C18, and added 5μl R2 material to aid 
in CLIP retention. The makeshift column was calibrated with 2x12 μl 0.1%TFA, 
pressed through by a syringe. Then 20 μl eluted peptide (pH2) was applied on to the 
column and the column was then washed with 4x12 μl 0.1 %TFA. The peptides were 
then eluted with matrix by applying 1 μl αCN matrix unto the column, then applying 
the eluate to a spot on the MALDI-plate. 
The MALDI-TOF analysis was done on a Bruker Daltonics MALDI-TOF Mass 
spectrometer at the Proteomics Core Facility, Rikshospitalet, using Bruker Daltonics 
control and analytic software according to Bruker Daltonics specifications. The 
heigth of  the peaks in the MALDI-TOF mass spectrua produced are not directly 
comparable to peaks in other such spectra because the strength of the signal from 
each ion is dependent on many factors that vary between each sample. The peaks can 
be compared to other peaks within the same spectrum, however. The relative heigth 
of each peak then indicates the amount of that peptide. Each spectrum can also be 
compared to other spectra if the peak heigth is ignored. That is why no numbers have 
been given for the Y-axis of the MS-spectra presented in Results, as the units used are 
abitrary and of no use for 
comparissons with other such 
spectra.   
 
Figure 16: MALDI-TOF MS Schematic 
(Applied Biosystems), showing the ions 
path through the flight tube. 
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3. Results 
3.1 Mutagenesis 
The two MHC class II molecules studied in this thesis, HLA-DQ2.2 and HLA-
DQ2.5, differ in only 10 residues in the membrane distal domain of the alpha chain. 
Table 4 shows the full sequence of both genes and their polypeptide chains, and 
where the polymorphisms are located. To study the effect on CLIP presentation these 
polymorphisms may have, mutations were introduced in position α31 (glutamine to 
glutamate), α37 (glycin to glutamate) and α72 (serine to isoleucine) in HLA-DQ2.5. 
In HLA-DQ2.2, mutations were introduced in position α31 (glutamate to glutamine) 
and α37 (glutamate to glycin). This is shown in figure 17. Note that the mutagenesis 
of HLA-DQ2.5 in position α72 introduces the codon ATT instead of ATC, but they 
both code for isoleucin. The presence of the C is thus not relevant for the study of the 
translated protein. The plasmid with HLA-DQ2.2 mutated in position α72 failed 
when used for retroviral transduction, and that mutation is not shown. 
The DQA1*0201 and DQA1*05 DNA sequences have previously been created by 
cDNA synthesis from B-cells. For mutagenesis, the genes were inserted in the 
pMOS-Blue vector which was used for bacterial transformation cloning and 
mutagenesis with the Stratagene Kit described in 2.6. The constructs were subcloned 
in XL-1 bacteria. The successful mutant genes were sequenced (2.7, figure 17) and 
transferred to the expression vector (2.2). 
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Table 4: DQ2 α-chain  sequences,  wild-type DNA54 55  and peptide sequences55 56 of DQA1*05 and 
DQA1*0201. The DNA sequence in italicized black, aa residues in grey, membrane distal polymorphic 
residues are marked in bold black. 
DQA1*05 
ATGATCCTAAACAAAGCTCTGATGCTGGGGGCCCTTGCCCTGACCACCGTGATGAGCCCC 
 M  I  L  N  K  A  L  M  L  G  A  L  A  L  T  T  V  M  S  P  
TGTGGAGGTGAAGACATTGTGGCTGACCACGTCGCCTCTTATGGTGTAAACTTGTACCAG 
 C  G  G  E  D  I  V  A  D  H  V  A  S  Y  G  V  N  L  Y  Q  
TCTTACGGTCCCTCTGGCCAGTACACCCATGAATTTGATGGAGATGAGCAGTTCTACGTG 
 S  Y  G  P  S  G  Q  Y  T  H  E  F  D  G  D  E  Q  F  Y  V  
GACCTGGGGAGGAAGGAGACTGTCTGGTGTTTGCCTGTTCTCAGACAATTTAGATTTGAC 
 D  L  G  R  K  E  T  V  W  C  L  P  V  L  R  Q  F  R  F  D  
CCGCAATTTGCACTGACAAACATCGCTGTCCTAAAACATAACTTGAACAGTCTGATTAAA 
 P  Q  F  A  L  T  N  I  A  V  L  K  H  N  L  N  S  L  I  K  
CGCTCCAACTCTACCGCTGCTACCAATGAGGTTCCTGAGGTCACAGTGTTTTCCAAGTCT 
 R  S  N  S  T  A  A  T  N  E  V  P  E  V  T  V  F  S  K  S  
CCCGTGACACTGGGTCAGCCCAACATCCTCATCTGTCTTGTGGACAACATCTTTCCTCCT 
 P  V  T  L  G  Q  P  N  I  L  I  C  L  V  D  N  I  F  P  P  
GTGGTCAACATCACATGGCTGAGCAATGGGCACTCAGTCACAGAAGGTGTTTCTGAGACC 
 V  V  N  I  T  W  L  S  N  G  H  S  V  T  E  G  V  S  E  T  
AGCTTCCTCTCCAAGAGTGATCATTCCTTCTTCAAGATCAGTTACCTCACCCTCCTCCCT 
 S  F  L  S  K  S  D  H  S  F  F  K  I  S  Y  L  T  L  L  P  
TCTGCTGAGGAGAGTTATGACTGCAAGGTGGAGCACTGGGGCCTGGACAAGCCTCTTCTG 
 S  A  E  E  S  Y  D  C  K  V  E  H  W  G  L  D  K  P  L  L  
AAACACTGGGAGCCTGAGATTCCAGCCCCTATGTCAGAGCTCACAGAGACTGTGGTCTGC 
 K  H  W  E  P  E  I  P  A  P  M  S  E  L  T  E  T  V  V  C  
GCCCTGGGATTGTCTGTGGGCCTCGTGGGCATTGTGGTGGGCACTGTCTTCATCATCCGA 
 A  L  G  L  S  V  G  L  V  G  I  V  V  G  T  V  F  I  I  R  
GGCCTGCGTTCAGTTGGTGCTTCCAGACACCAAGGGCCCTTGTGA 
 G  L  R  S  V  G  A  S  R  H  Q  G  P  L  -   
 
DQA1*0201 
ATGATCCTAAACAAAGCTCTGATGCTGGGGGCCCTCGCCCTGACCACCGTGATGAGCCCT 
 M  I  L  N  K  A  L  M  L  G  A  L  A  L  T  T  V  M  S  P 
TGTGGAGGTGAAGACATTGTGGCTGACCACGTTGCCTCTTACGGTGTAAACTTGTACCAG 
 C  G  G  E  D  I  V  A  D  H  V  A  S  Y  G  V  N  L  Y  Q 
TCTTACGGTCCCTCTGGCCAGTTCACCCATGAATTTGATGGAGACGAGGAGTTCTATGTG 
 S  Y  G  P  S  G  Q  F  T  H  E  F  D  G  D  E  E  F  Y  V 
GACCTGGAGAGGAAGGAGACTGTCTGGAAGTTGCCTCTGTTCCACAGACTTAGATTTGAC 
 D  L  E  R  K  E  T  V  W  K  L  P  L  F  H  R  L  R  F  D 
CCGCAATTTGCACTGACAAACATCGCTGTGCTAAAACATAACTTGAACATCCTGATTAAA 
 P  Q  F  A  L  T  N  I  A  V  L  K  H  N  L  N  I  L  I  K   
CGCTCCAACTCTACCGCTGCTACCAATGAGGTTCCTGAGGTCACAGTGTTTTCCAAGTCT 
 R  S  N  S  T  A  A  T  N  E  V  P  E  V  T  V  F  S  K  S  
CCCGTGACACTGGGTCAGCCCAACACCCTCATCTGTCTTGTGGACAACATCTTTCCTCCT 
 P  V  T  L  G  Q  P  N  T  L  I  C  L  V  D  N  I  F  P  P  
GTGGTCAACATCACCTGGCTGAGCAATGGGCACTCAGTCACAGAAGGTGTTTCTGAGACC 
 V  V  N  I  T  W  L  S  N  G  H  S  V  T  E  G  V  S  E  T 
AGCTTCCTCTCCAAGAGTGATCATTCCTTCTTCAAGATCAGTTACCTCACCTTCCTCCCT 
 S  F  L  S  K  S  D  H  S  F  F  K  I  S  Y  L  T  F  L  P 
TCTGCTGATGAGATTTATGACTGCAAGGTGGAGCACTGGGGCCTGGATGAGCCTCTTCTG 
 S  A  D  E  I  Y  D  C  K  V  E  H  W  G  L  D  E  P  L  L 
AAACACTGGGAGCCTGAGATTCCAGCACCTATGTCAGAGCTCACAGAGACTGTGGTCTGT 
 K  H  W  E  P  E  I  P  A  P  M  S  E  L  T  E  T  V  V  C 
GCCCTGGGGTTGTCTGTGGGCCTCGTGGGCATTGTGGTGGGGACCGTCTTGATCATCCGA 
 A  L  G  L  S  V  G  L  V  G  I  V  V  G  T  V  L  I  I  R 
GGCCTGCGTTCAGTTGGTGCTTCCAGACACCAAGGGCCCTTGTGA 
 G  L  R  S  V  G  A  S  R  H  Q  G  P  L  - 
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DQA1*0201 E31Q (GAG →CAG) 
 
DQA1*0201 E37G (GAG → GGG) 
 
DQA1*05 Q31E (CAG→GAG) 
 
DQA1*05 G37E (GGG→GAG) 
 
DQA1*05 S72I (AGT→ATT) 
 
Figure 17: Sequences of mutated polymorphic sites with mutated base-pairs marked with a frame. 
Consensus sequence is shown on top, then the wt gene and polypeptide chain. The mutated gene is shown on 
the bottom.  The comparison of sequences was done using SecScape2.5 (Applied Biosystems).  
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3.2 Flow cytometry 
The expression vector containing the mutated α –chain genes were retroviraly 
transduced into EBV-transformed B-cells as described in the methods part of this 
thesis. These cells were grown to a density of at least 400,000 cells/ml, and then used 
for flowcytometry on a FACSCalibur flowcytometer (2.11).  
 721.82 wt gate plot         
 
 
 
 
 
 
  721.82 HLA-DQ2 compensation        721.82 HLA-DQ2 isotype control 
       
 
 
 
 
Figure 18: Flow cytometry calibration a) Gate shown on unmarked 721.82 cells, the gate was used for all 
cytometry measurements. b) Compensation with 721.82 HLA-DQ2.5 cells, c) Isotype control using 721.82 cells 
to show that no unspecific reactions are present. See 2.11 for methodology details. 
 52 
 
 721.82 HLA-DQ2.5wt               721.82 HLA-DQ2.5Qα31E 
  
 
 
 
 
 
721.82 HLA-DQ2.5Gα37E              721.82 HLA-DQ2.5Sα72I 
 
 
 
 
 
 
 
721.82 HLA-DQ2 negative control 
Figure 19: Flow cytometry plots for cells 
expressing HLA-DQ2.5 mutants. Signal 
intensity of HLA-DQ2 (PE) vs. CLIP(FITC). 
The negative control has not been labeled 
with any antibodies. Note that the scale is 
logarithmic on both axes.  
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The flow cytometry results from HLA-DQ2.5 are presented in figure 19. Contour 
plots of the wild type (wt) cell population and the three populations expressing 
mutant HLA-DQ2.5 show that there is a distinct increase in CLIP surface 
presentation from wt to mutants. 
The largest increase is seen with the mutation in position α72, an isoleucine replacing 
a serine. The α72 plot shows a marked increase in CLIP signal at a given level of 
HLA-DQ2.5, compared to the wt plot. The plot for HLA-DQ2.5 mutated in position 
α31, exchanging glutamine for glutamate, shows a more modest increase of CLIP 
signal. The last mutant, glycin exchanged for glutamate in position α37, shows a 
small increase of CLIP signal compared to wt, but not as much as the other two 
mutants. However, the lower overall HLA-DQ2.5 expression in the α37 mutated cell 
population will increases the effect of HLA-DM. The observed lower CLIP 
presentation can be partially explained by this higher HLA-DM effect. 
The flow cytometry of HLA-DQ2.5 shows that all the mutations in the three target 
polymorphic sites increase CLIP presentation the binding groove, with the residue at 
α72 providing the most pronounced increase. 
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 721.82 HLA-DQ2.2wt                                 721.82 HLA-DQ2.2 E31Q                          
 
 
 
 
 
 
  
721.82 HLA-DQ2.2 E37G    721.82 HLA-DQ2 negative control 
 
 
 
 
 
 
 
Figure 20: Flow cytometry plots for cells expressing HLA-DQ2.5 mutants. Signal intensity of HLA-DQ2 (PE) 
vs. CLIP(FITC). The negative control has not been labeled with any antibodies.   
 55
The flow cytometry results from HLA-DQ2.2 wt and the two successfully mutated 
HLA-DQ2.2 mutant molecules show that the mutations have little effect on CLIP 
presentation. These plots are shown in figure 20. The same kind of plots has been 
used for HLA-DQ2.2 as for HLA-DQ2.5, and they can be interpreted the same way. 
All the plots show a relatively high expression of surface HLA-DQ2.2, but low CLIP 
signals even with large amounts of HLA-DQ2 expressed. The observed low CLIP at 
relative high expression levels indicates poor CLIP stability in the binding groove. 
Interestingly, the wt HLA-DQ2.2 plot has a much higher HLA-DQ2 signal than any 
of the mutants of HLA-DQ2.5. Yet, even at 10X the DQ2 expression the amount of 
CLIP is barely equal to the HLA-DQ2.5 α72 mutant.  
The cells expressing HLA-DQ2.2 with mutation in α31 and α37 have a lower HLA-
DQ2.2 expression than the wild-type, and the plot shows no CLIP presentation 
compared to the negative control.  These results indicate that the introduced 
mutations in HLA-DQ2.2 lowered the amount of CLIP presented. Even at high HLA-
DQ2.2 expression, the CLIP amount is not comparable to HLA-DQ2.5 wt and 
mutants. This serves to confirm the observations from the HLA-DQ2.5 mutations, 
since the opposite mutations seem to have the opposite effect. 
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3.3 Mass spectrometry 
Retroviraly transduced 721.82 B-cells were harvested and lysed, and the MHC 
molecules were purified. The peptides were eluted from the binding groove as 
described in 2.12 and 2.13. MALDI-TOF mass spectrometry was then performed on 
the eluted peptides (2.14). 
HLA-DQ2.5 wt         HLA-DQ2.5 Qα31E 
 
 
 
 
 
 
HLA-DQ2.5 Gα37E     HLA-DQ2.5 Sα72I 
 
 
 
 
 
 
 
Figure 21: MALDI-TOF spectra of HLA-DQ2.5.  Mass/charge along the X-axis, arbitrary units along the Y 
axis. Peaks that have been identified as CLIP are marked with stars. *: 2333.3 m/z, **:2430.4m/z, 
***:2543.4m/z.  
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The spectra from MALDI-TOF of HLA-DQ2.5 wt and mutants are shown in figure 
21. The wt HLA-DQ2.5 spectrum is dominated by CLIP peptide peaks, with other 
endogenous peptides also evident. Note that CLIP easily ionize, due to the K and R 
residues in the peptide. This may make the CLIP peptides appear more aboundant 
than they acctualy are, and will tend to skew the spectra so that CLIP peptides always 
show up with a strong signal while some endogenous petides might not show up at 
all.  
The spectrum from HLA-DQ2.5 Qα31E shows as large or larger amounts of CLIP 
presentation compared to wt, but the spectrum is slightly distorted because of the 
very strong signal from the oxidized peptide. That makes the results more unreliable 
from this spectrum. The largest differences can be seen in the spectra for HLA-DQ2.5 
Gα37E and Sα72I, both completely dominated by the CLIP peaks. The amount of 
other peptide is likely larger than can be seen in the spectra, but the CLIP signal for 
both these samples is so strong that it is clear that the amount of CLIP is 
considerable. This confirms the flow cytometry results showing that a larger amount 
of CLIP peptides are presented on the mutant HLA-DQ2.5 compared to wild type in 
the molecules mutated in position α37 and α72, and to a lesser degree for the 
molecules mutated in α31. 
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HLA-DQ2.2             HLA DQ2.2 E31Q 
 
 
 
 
 
 
HLA-DQ2.2 E37G 
 
 
 
 
 
Figure 22: MALDI-TOF spectra of HLA-DQ2.2.  Mass/charge along the X-axis, arbitrary units along the Y 
axis. Peaks that have been identified as CLIP are marked with stars. *: 2333.3 m/z, **:2430.4  
The spectra for wt HLA-DQ2.2 and mutants are shown in figure 22. Two low CLIP 
peptide peaks in the wt HLA-DQ2.2 spectrum are seen. The peaks are not dominating 
the spectrum as with HLA-DQ2.5. As CLIP is easily ionziable, this means that the 
amount of CLIP present is likely very small. Both the mutant spectra show only a 
large amount of different endogenous peptides, with no single peak dominating the 
spectra. No distinct CLIP peptide peaks can be found. This confirms the flow 
cytometry results showing that mutations in HLA-DQ2.2 position α31 and α37 either 
lower or have no effect on the amount of CLIP presented in the binding groove of 
HLA-DQ2.2. 
 59
4.  Discussion 
Autoimmune diseases are largely a conundrum even after decades of research on the 
subject. Especially the molecular and genetic backgrounds of such disorders have 
been under close scrutiny. Genetic predisposition for autoimmune diseases is tied 
largely to the MHC region of chromosome 6. Considering the vital part MHC class I 
and MHC class II peptide presentation play in the activation of the adaptive immune 
response, this is not surprising. Celiac disease is an example of a condition where a 
MHC class II gene, in the form of HLA-DQ2.5, is strongly associated with the 
disease. The very similar HLA-DQ2.2 molecule is not associated with celiac disease. 
The two molecules are highly similar, and their membrane distal domains contain 
only 10 polymorphic residues in the alpha-chain. The molecules have similar peptide 
binding motifs and both bind gluten T-cell epitopes. However, they do show a 
marked difference in CLIP presentation in the peptide binding groove has been 
observed between the two HLA molecules. HLA-DQ2.5 is known to present CLIP 
peptides, while HLA-DQ2.2 is not. Combined with the recent discovery that both 
HLA-DQ2 molecules appear to be poor substrates for HLA-DM1,38, there are 
indications that the differences in CLIP presentation can be explained by 
investigating the 10 polymorphic residues in their membrane distal domains. The 
results from part of that investigation are presented in this thesis. 
The membrane distal polymorphic sites in the alpha-chain of HLA-DQ2.5 and HLA-
DQ2.2 are designated α22, α31, α37, α44, α47, α48, α49, α50, α51 and α72. Of these 
polymorphisms, α44 and α47-51 are located in a region of HLA-class II thas is 
suggested to be involved in the HLA-DM interaction mechanism24,25. The other 4 
polymorphic sites are located in or around the peptide binding groove. The location 
of all of the polymorphic sites can be seen in figure 9.  
As described in the introduction, the binding groove of the MHC-class II molecules 
contain binding pockets that interact with the side chains of the peptide in the groove. 
Combined with hydrogen bonds to the peptide backbone from invariant anchor 
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residues, these interactions bind the peptide to the binding groove57. The polymorphic 
sites in the area around the binding groove might be involved in this anchoring, and 
were thought to be interesting targets for studying the cause of the differences in 
CLIP presentation mentioned above. This thesis work focused on the effects of the 
polymorphic residues α31, α37 and α72. 
In this thesis, flow cytometry and mass spectrometry data from mutated HLA-DQ2.5 
and HLA-DQ2.2 have been presented. The mutated HLA-DQ2.5 molecules have had 
a residue in one of the 3 target polymorphic sites exchanged for one normally present 
in the HLA-DQ2.2 molecule. This creates 3 different mutant HLA-DQ2.5 molecules 
with a single residue from HLA-DQ2.2. The results show that such a mutation in any 
of the three polymorphic sites investigated increase the amount of CLIP peptide 
presented by the mutant molecule, when compared to wt HLA-DQ2.5. The greatest 
effect is seen with a mutation of serine to isoleucine in position α72.  
The large amount of CLIP presented by wt HLA-DQ2.5 was earlier reported by Van 
De Wal et.al 58 and Vartdal et.al59 investigating the binding of peptides to the DQ2 
groove. The results reported in this thesis indicate that the wt residues (Q,G and S) in 
position α31, α37 and α72 of HLA-DQ2.5 do not increase CLIP presentation. Those 
residues may in fact have a limiting effect on the CLIP presentation reported in the 
above papers. This hypothesis was partially confirmed by doing the reverse mutation, 
introducing the residues from HLA-DQ2.5 into HLA-DQ2.2. The mass spectrometry 
and flow cytometry data presented here from the HLA-DQ2.2 mutants show that 
introducing the HLA-DQ2.5 residues in the target polymorphic sites either have no 
effect or reduce the CLIP presentation of those molecules. Together, these results 
indicate that the residues in the polymorphic sites α31, α37 and α72 do not explain 
the high CLIP presentation of HLA-DQ2.5, but on the contrary increase the peptide 
affinity of HLA-DQ2.2. 
It must be mentioned that the reverse mutation experiment did not succeed for the 
residue in position α72 of HLA-DQ2.2 (isoleucine exchanged with serine). The DNA 
mutated to express serine in position α72 failed repeatedly to retroviraly transduce the 
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target B-cells. Retroviral transduction of B-cells is a very delicate process, and only a 
small amount of cells are successfully transduced and survive the antigenic selection 
process. The most likely explanation of the failure in this case is that impure plasmid 
DNA was used for the transfection of the packaging cells. Unstable DNA or the 
presence of proteins would disrupt the transfection process. If a new expression 
vector that includes the mutated gene could be constructed, there is no reason the 
transduction should not work. 
The results presented in this thesis are a separate and independent work, and show the 
influence of the polymorphic residues in position α31, α37 and α72 on the 
presentation of CLIP by HLA-DQ2.5 and HLA-DQ2.2. The results show that these 
sites are do not explain for the high CLIP presentation of HLA-DQ2.5, but are 
involved in increasing peptide affinity in HLA-DQ2.2. The results also indicate that 
these polymorphic sites have an effect on CLIP presentation in both molecules, and 
that they are somehow limiting the CLIP presentation seen in wt HLA-DQ2.5. 
Introduction of HLA-DQ2.2 residues in the polymorphic positions of HLA-DQ2.5 
creates even better CLIP presenting molecules, while HLA-DQ2.5 residues 
introduced in HLA-DQ2.2 remove the meager CLIP presentation shown in the HLA-
DQ2.2 wt. How can this be explained?  
To understand how these observed effects may be related to CLIP presentation and 
stability in HLA-DQ2.5, the results from the rest of the study by the Sollid group will 
have to be included and discussed. Fallang et.al.1 shows that mutations in the 
presumed DM-interaction area (α 44 and α 47-51) have little effect on the HLA-
DQ2.5 CLIP presentation. The reverse mutations in HLA-DQ2.2 were not done, as 
little effects on HLA-DQ2.5 were observed. The mutation of position α22 from a 
tyrosine to a phenylalanine in HLA -DQ2.5 has a much more pronounced effect, 
which removes CLIP presentation completely from HLA-DQ2.5. The reverse 
reaction shows an equally pronounced effect that increase the CLIP presentation on 
the HLA-DQ2.2 to a level far beyond wt HLA-DQ2.5, or even the HLA-DQ2.5 α72 
mutant presented in this thesis. These results are shown in Figure 23. 
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Figure 23: MALDI-TOF results from Fallang et.al, 
20091. The HLA-DQ2.5 α44, α47-51 mutant presents the 
same amount of CLIP as wt HLA-DQ2.5. Loss of CLIP 
presentation is clear in the HLA-DQ2.5 mutated in 
position α22. Very distinct and high CLIP peaks are seen 
from the HLA-DQ2.2 molecules mutated in position α22. 
 
 
 
 
The implications from the results presented above are that tyrosine in position α22 is 
the main factor determining CLIP presentation in the HLA-DQ2.5 binding groove. 
The polymorphism in position α22 is critical for explaining the difference in CLIP 
presentation between the two HLA-DQ2 molecules, but the  results presented in this 
thesis makes it clear that the situation is a little more complex.  
The mutant HLA-DQ2.2 with tyrosine in position α22 has an extreme amount of 
CLIP presentation, much higher than wt HLA-DQ2.5. The results obtain in this thesis 
indicate that the residues in position α31, α37 and α72 of HLA-DQ2.2 (E, E and I) 
increase CLIP binding when combined with the tyrosine in position α22, as shown in 
figure 21, and allows for CLIP binding even if no tyrosine is present (figure 22). 
Conversely, the residues in position α31, α37 and α72 of HLA-DQ2.5 (Q,G and E) 
lowers the CLIP binding when combined with tyrosine in α22, and also if combined 
with a phenylalanine in the same position.  
The combination of all of the residues that increase CLIP binding, as in HLA-DQ2.2 
with tyrosine introduced in position α22, gives a combined effect of extreme CLIP 
presentation. The removal of all such residue, as in HLA-DQ2.5 with phenylalanine 
in position α22, gives no CLIP presentation. While the polymorphic residue in 
position α22 is the most important residue for explaining the CLIP presentation; the 
three polymorphic sites studied in this thesis also have a clear effect in combination 
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with α22. Wild-type HLA-DQ2.5 lacks the glutamates and isoleucine in position α31, 
α37 and α72 and as such is not as strong a CLIP presenter as it could be. HLA-DQ2.2 
has those residues in the polymorphic sites and can thus present a small amount of 
CLIP even without the tyrosine in α22. 
Combined, these results explain the disparity of CLIP presentation between HLA-
DQ2.2 and HLA-DQ2.5. They do not explain how and why the presence of a certain 
residue in these polymorphic sites can influence CLIP presentation on the cell 
surface, however. Other results indicate that the residues increase or decrease the 
stability of CLIP binding in the groove of the MHC class II molecules. Binding 
stability will have an increased importance since it has been indicated that both HLA-
DQ2 molecules are poor substrates for HLA-DM1,38. Fallang et.al.1 proposes that the 
tyrosine in position α22 can engage in a hydrogen bond to the peptide backbone of 
the bound peptide to increase stability. The importance of such a H-bond between 
polymorphic residue and the peptide backbone has not been previously studied, not 
has it been implicated in pathogenesis of a disease (Figure 24). How the polymorphic 
residues in α31, α37 and α72 would influence the stability of CLIP in the binding 
groove is not known, and more experiments and crystal structure of DQ2.2 would 
have to be completed before a hypothesis could be presented. The results in this 
thesis only indicate that all of the mentioned positions are important for CLIP binding 
stability, α72 in particular. 
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Figure 24: Hydrogen binding network surrounding tyrosine in position α22 in HLA-DQ2.5, showing how 
the tyrosine can induce a stronger hydrogen bond network through H2O. α-I-gliadin bound to the groove 
(white), oxygen (black), hydrogen bonds shown in dashed lines. Numbers show distances in Å. Illustration from 
Fallang.et.al.1. 
CLIP stability in the binding groove should be comparable to the stability of other 
peptides in the binding groove. Fallang et.al1 shows that APCs expressing wt HLA-
DQ2.5 have protracted antigen presentation after encounter with gliadin peptides, 
compared to APCs expressing wt HLA-DQ2.2. Gliadin peptides seem to bind to the 
wt HLA-DQ2.5 with higher stability than wt HLA-DQ2.2, and are able to stimulate 
T-cells for a longer time. HLA-DQ2.2 which has been mutated in position α22 to 
express tyrosine instead of phenylalanine shows the same ability for protracted 
antigen presentation. The reverse mutation introduced in HLA-DQ2.5 removes this 
ability. There are no such experiments for the polymorphic residues studied in this 
thesis, but the ones from Fallang.et.al1 confirm that the high presentation of CLIP in 
HLA-DQ2.5  is due to increased peptide stability in the groove. They also show that 
the increases or decreases in stability are influenced by the polymorphic residues, and 
are not limited to CLIP peptides only. These results support that the conclusion of 
this thesis; that the effects of the polymorphisms in α31, α37 and α72 on CLIP 
presentation are due to changes in binding stability. 
The main question surrounding the differences between HLA-DQ2.5 and HLA-
DQ2.2 is still their different association to celiac disease. Can larger amounts of CLIP 
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presentation and longer CLIP binding stability explain part of this difference? It is 
well known that T-cells are negatively and positively selected in the thymus, and that 
central tolerance to self-peptides is induced there. This is done by the thymus 
epithelial cells, which express MHC class II and the AIRE transcription factor. 
Peptides from every tissue are presented on the MHC class II molecules in the 
thymus and used for negative selection of autoreactive T-cells5. HLA-DQ2.5 would 
present large amount of CLIP peptides on these epithelial cells, which might 
influence development of self-tolerance in unknown ways, perhaps leading to the 
development of autoreactive T-cells. 
Protracted antigen presentation can play a critical role in the initiation of a T-cell 
response to an antigen. Following antigen loading, the journey for an APC from 
tissue to a draining lymph node may last up to 48 h. During that time, the bound 
peptide can easily be lost if the stability of the binding is low. In addition, T-cells are 
more easily activated by stabile peptides that can participate in longer T-cell 
interactions 60,61. Henrickson et.al.62 recently showed that T-cell activation is 
dependent on the antigen dose that is presented by APCs. They also show that there is 
a threshold of antigens which must be reached before a T-cell response is activated. A 
MHC class II molecule that binds gluten T-cell epitopes with low stability might be 
unable to retain enough such antigens to activate a T-cell response. A molecule where 
such peptides are more stabile would likely be able to reach the threshold for 
activation and start an immune response to the antigen.  
The stability of the binding of gliadin-peptides to HLA-DQ2.5 might be critical for 
the initiation of an autoimmune response against gluten. The polymorphic sites 
studied in this thesis  seem to work against the influence of the residue in position 
α22 in wild-type HLA-DQ2.5, lowering the stability of peptide binding. The 
characterization of this effect may have taken us a small step further in understanding 
celiac disease and other HLA-associated autoimmune diseases, as that peptide 
binding stability may be at the heart of the association of HLA-DQ2.5 with such 
diseases. 
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5. Further prospects 
Some of the results from this thesis have already been part of a publication by the 
Sollid group1, but there are still many ways to take the project further. The mutation 
in position α72 of HLA-DQ2.2 will need to be tested to show that an isoleucine in 
this position has the predicted effect. Dissociation studies and protracted antigen 
presentation studies for all 3 polymorphic residues studied here would help confirm 
the effect of these polymorphic sites on the binding stability of non-CLIP peptides.   
A major goal would be to be able to crystallize the CLIP-DQ2.2 complex and do X-
ray crystallography of its structure, to measure potential hydrogen bonds and see the 
effect of the isoleucine in position α22.  
Knowing which residues influence gliadin peptide stability in the HLA-DQ2.5 
binding groove may also be of interest as target sites for development of potential 
medication against autoimmune HLA-linked diseases like celiac disease.  
Lastly, there are many other autoimmune diseases linked to HLA-molecules similar 
to HLA-DQ2.5. The Sollid group has already started a project to investigate the 
tyrosine in position α22 of HLA-DQ8. Position α31, α37 and α72 in HLA-DQ8 
might also be of interest if this study finds any difference in HLA-DQ8 peptide 
stability when position α22 is mutated.  
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